More than 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis

 Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers.

 

To order this 375+ page report, which features 180+ figures and 195+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

 

The USD 1.7 billion financial opportunity (by 2030) within the ophthalmic drugs contract manufacturing market has been analyzed across the following segments:

§  Type of product

§  Ophthalmic API

§  Ophthalmic drug FDF

 

§  Type of FDF manufactured

§  Solid

§  Semi-solid

§  Liquid / suspension

 

§  Type of primary packaging

§  Ampoule / vial 

§  Glass / plastic bottle

§  Ointment tube

§  Blister packing

§  Other forms

 

§  Scale of manufacturing

§  Clinical

§  Commercial

 

§  Company size

§  Small

§  Mid-sized

§  Large

§  Very large

 

§  Target disease indication

§  Age-related macular degeneration

§  Dry eye

§  Glaucoma

§  Other disease segments

 

§  Key geographical regions

§  North America (US, Canada and Mexico)

§  Europe (UK, Germany, France, Spain, Italy and rest of Europe)

§  Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)

§  Rest of the world

 

The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.” report features the following companies, which we identified to be key players in this domain:

§  Akorn

§  Akums

§  Bal Pharma

§  Catalent

§  Cayman Chemical

§  Entod Pharmaceuticals

§  Farmigea

§  Glenmark Pharmaceuticals

§  Indiana Ophthalmics

§  Lomapharm

§  Medichem

§  Pillar5 Pharma

§  Recipharm

§  Salvat

§  Sterling Pharmaceutical Services

§  Sunways India

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Current Market Landscape

5. Company Competitiveness Analysis

6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles

7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles

8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles

9. Clinical Trial Analysis

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies

14. SWOT Analysis

 

15. Survey Analysis

 

16. Executive Insights

 

17. Future Growth Opportunities

 

18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers

 

19. Appendix 2: Tabulated Data

 

20. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more